Abstract: Ultrasound-guided biopsies in the abdomen and pelvis are generally more effective, safer, faster, and cheaper than those performed under computed tomography guidance. This manuscript will discuss multiple aspects of sonographic biopsies performed between the diaphragm and the symphysis pubis. We begin with systems issues, patient preparation (including bleeding profile and anticoagulant use), pain management, and infection precautions. The procedure itself is then analyzed, including needle guidance, the role of the sonographer, image optimization, patient positioning, coreversus fine-needle aspiration, coaxial versus individual pass, needle technique, and postprocedure management. Issues specific to different sites are then discussed: liver, spleen, pancreas, kidney, adrenal, bowel, retroperitoneum and mesentery, and the pelvis. We finish with a discussion of complications, future trends, and a brief summary.
T he advent of percutaneous image-guided biopsy has been a huge boon to patients, generally sparing them the morbidity of operative procedures for tissue characterization. Ultrasound guidance for these procedures is possible in most cases in the abdomen and pelvis and is often safer, quicker, and less expensive and has a higher diagnostic yield than other image guidance modalities. The goal of this article is to present techniques for ultrasound-guided biopsies in a variety of common and not-so-common scenarios in the abdomen and pelvis, potentially expanding the use of sonography in these situations and thereby bringing the benefits of ultrasound to more of our patients.
HISTORY
Although primacy is notoriously difficult to accurately assess, some of the earliest ultrasound-guided procedures were reported in 1972 by Goldberg and Pollack 1 with the demonstration of their dedicated aspiration transducer. 2 Computed tomography (CT) followed closely behind, with the first reported CT-guided biopsy performed by Alfidi et al 2 in 1975 . 3 Ultrasound-guided needle placement grew steadily in the ensuing decades. The aptly entitled article of Dodd et al, 4 BSonography: The Undiscovered Jewel of Interventional Radiology,[ led to even more popularity for sonographically guided procedures.
INDICATIONS
The reasons for percutaneous biopsy are broad and expanding. These include the need for tissue characterization of an abdominal mass, confirmation of metastatic disease to direct therapy or counsel patients, confirmation of a specific tumor type for a clinical trial (a very large potential future application of percutaneous biopsy as cancer treatments become more specific for different tumors), evaluation for infection in a fluid collection, evaluation for parenchymal disease in native organs (typically the kidney and liver), and evaluation for transplant organ rejection. As abdominal radiologists, we appreciate the potential advantages of hightech, noninvasive imaging; having said that, we definitely agree with one speaker who said Bthe most useful additional MR pulse sequence for lesion characterization is the 18-ga needle[! Another perspective was given by one of the memorable characters in Samuel Shem's classic novel, BThe House of God,[ who stated Bthere is no body cavity that cannot be reached with a 14-gauge needle and a good strong arm. [ 5 What not to biopsy? All medical decision making is a risk-benefit analysis, so there are very few absolute contraindications to biopsy. An excellent relationship and open communication with the referring physician are crucial to good radiological medical decision making; in addition, the radiologist needs to think like a clinician, know his or her patient's medical history, and understand the clinical problem to be solved by the biopsy.
For example, performing a biopsy of a highly suggestive hypervascular mass in a cirrhotic liver in the face of an elevated >-fetoprotein (AFP) is not necessary 6 Vthe very high likelihood of hepatocellular carcinoma (HCC) in this setting makes tissue confirmation not worth the small but nonzero risk of bleeding and/or seeding. In the past, percutaneous biopsy of renal masses was actively discouraged; recent improvements in pathological techniques, increasing evidence suggesting that the risk of tumor seeding is minimal, and new treatments for renal cell carcinoma (RCC), however, have led to a marked
CHOICE OF IMAGING MODALITY FOR GUIDANCE
This decision can essentially be simplified to a choice between ultrasound versus CT. Although magnetic resonance imaging (MRI) guidance is possible and has some advantages, in practice the specialized expensive equipment required precludes widespread use of this technology. Fluoroscopy is widely available but rarely used in soft tissue biopsies of the abdomen and pelvis due to its inherent disadvantages in these areas. The choice between CT and ultrasound is a multifactorial decision that should be individualized on a case-bycase basis. In general, a radiologist should consult with the referring physician and direct each case to the appropriate guidance modality; this direct physician-to-physician communication optimizes patient care and minimizes the probability of poor outcomes.
In our abdominal imaging section, approximately 98% of the abdominal and pelvic biopsy procedures are performed using ultrasound guidance. In 2006, 15% of our 16,000 total annual ultrasound examinations (these statistics do not include breast imaging) are procedures involving ultrasound guidance for needle placement, whether they are simple thoracentesis and paracentesis, easy tissue sampling such as thyroid fineneedle aspiration (FNA), slightly more challenging solid organ core biopsy, or very difficult subcentimeter interaortocaval lymph node sampling. In general, if the mass or target can be seen with ultrasound, a biopsy will be performed under ultrasound rather than CT.
Advantages of ultrasound include real-time imaging guidance (safety), speed of use, the ability to compress the abdomen and get closer to your target, lower cost of capital equipment versus CT, rapid confirmation of complications (bleeding), higher success rates, portability, and lack of radiation exposure to the patient and medical staff. Advantages of CT include visualization of certain structures that can be difficult to see with ultrasound (eg, adrenal, calcified masses, retroperitoneal structures, lung parenchymal lesions) and the comfort of many radiologists with CT technology. Computed tomography fluoroscopy 7 has increased the speed and procedure safety with which CT-guided biopsies can be performed, although the radiation exposure associated with this technology is not trivial. 8, 9 Several of the advantages listed above in sonography are self-evident (eg, real-time guidance and portability). Others have been analyzed in a direct fashion. Kliewer et al, 10 commenting on the fact that cost minimization will be one of the principal determinants of success in the marketplace as the economics of health care change in our country, found that CT guidance is 1.89 times more expensive than ultrasound guidance for percutaneous liver biopsy. In their decision analysis, they justify usage of a 78% probability of obtaining an adequate sample using CT guidance, versus a higher 87% for sonographic guidance (although please note that we are not aware of a randomized trial that actually directly compares biopsy success rates between CT and ultrasound); in our opinion, the ease of real-time confirmation of needle passage directly through the lesion with ultrasound is one of the primary reasons that ultrasound may have a higher adequate sample rate. Although time spent on any procedure depends heavily on patient selection and operator expertise, one study comparing durations for ultrasound versus CT guidance for abdominal interventional procedures found an average room time of 77 minutes for ultrasound guidance versus 99 minutes (22 minutes longer) for the CT group. 11 The advent of CT fluoroscopy has decreased the time necessary for a successful procedure when compared with helical CT; these improvements in needle placement times have been estimated at between 20% 9 and 66%. 12 However, in one phantom study, ultrasound with a needle guide still required less time than that with CT fluoroscopy. This publication also observed that improvements in needle placement time generally do not have a significant effect on overall room time (eg, CT fluoroscopy versus conventional CT), and hence, the costs incurred. The inherent ultrasound scan biopsy procedure itself is advantageous as physicians attempt to cope with the difficulties brought upon by the Bobesity epidemic[ in our society 13 ; because of compression applied with the ultrasound probe upon the abdomen, the average distance from the skin surface to the lesion was reduced from an average of 8.8 cm with CT to 4.5 cm with ultrasound, 14 thereby facilitating tissue sampling.
SYSTEMS ISSUES
We have found the following 5 points to be very helpful in developing a successful biopsy program. First, emphasize to the sonographers the importance of their personally taking professional ownership of a successful biopsy service. Not all sonographers wish to embrace the responsibility inherent in interventional procedures, but those who enjoy it and take it seriously add immeasurable value to the patient. Second, work closely with pathologists and cytopathologists to ensure good communication and useful consultation. Third, a dedicated nurse clinician who is available for patient preparation, moderate sedation, and clinician consultation is invaluable. Fourth, standardized paperworks (orders, notes, patient education, etc) make the day run smoother. Finally, followup is incredibly important for organizational learning. For everything except thoracentesis, paracentesis, and thyroid FNA, the patient is called the next day to check on their well-being. All procedures are kept in a quality assurance database, and complications are tracked. 
PATIENT PREPARATION

Patient Preparation: Bleeding Profile
Published studies on bleed rates and bleeding profiles are tenuous at best. Prothrombin time (PT) and partial thromboplastin time (PTT) are routinely ordered worldwide for surgical patients, although studies consistently demonstrate the low diagnostic utility of this practice; preoperative PT and PTT values are poor predictors of abnormal bleeding after surgical procedures. 16 Indices of coagulation in the peripheral blood have been shown to be unreliable indicators of the risk of bleeding after liver biopsy. 17 The platelet count is reproducible but does not assess function, thereby providing incomplete and potentially misleading information. 18 To quote from the seminal paper by Erban et al 19 discussing the inappropriate use of the PT and PTT tests, BMany physicians consider tests like [these] to be inexpensive, Blittle-ticket[ items that will protect them from the hazards of litigation.[ For the interested reader, Eckman et al 18 provide an excellent review regarding screening for bleeding risk. They concluded that BIwithout synthetic liver dysfunction or a history of oral anticoagulant use, routine testing has no benefit in assessment of bleeding risk.[ Multiple studies have shown that obtaining a good history is the most important first step in determining whether testing is warranted.
However, partly because we have a large hepatology/ liver transplant service and therefore perform invasive procedures on many patients with synthetic liver dysfunction, and partly because of the pervasive fear of litigation discussed above (Bdefensive medicine[), we routinely obtain an international normalized ratio (INR) and platelet count on all intraabdominal biopsy patients. If the INR is less than 1.5 and the platelet count is greater than 50,000/mL, we will perform almost any procedure. International normalized ratio of greater than 1.5 and/or platelet count of less than 50,000/mL prompts discussion of the biopsy with the referring physician. Depending on the location of the target, the type of needle to be used, and so on, a decision is made whether to supplement the patient with a transfusion of fresh frozen plasma (FFP) and/or platelets. This is particularly an issue in the biopsy of cirrhotic livers where both INR and platelets are typically depressed. We routinely perform diagnostic and therapeutic paracentesis in our population of cirrhotic patients with liver failure if the INR is less than 2 without any infusion of FFP, but we always carefully look for and avoid the inferior epigastric arteries with Doppler before our paracentesis puncture.
What is the proper dose of FFP or platelets to give? The complexity of blood product replacement requires clinical consultation for proper patient care. Rough guidelines are given here, but realize that the details of this process are generally beyond the scope of a radiologist's practice. The recommended platelet transfusion dose is 1 U/10 kg of body weight when using random-donor pooled platelets; this should raise the platelet count by 40,000 to 50,000/mL, assuming normal platelet survival. However, many acutely ill patients have shortened platelet survival, patients with large spleens (eg, cirrhosis) will have lower platelet recovery, and patients who have autoimmune thrombocytopenia or who are alloimmunized to donor platelets may be difficult or impossible to correct. Proper dosing of FFP is also complex. The recommended dose of FFP is 10 to 20 mL/kg, or 4 to 6 U in the average adult (the volume of a typical unit is 200Y250 mL). However, the dose of FFP needed to achieve a given target goes up dramatically as the target INR goes down. 
Patient Preparation: Anticoagulant Use
This is another area where the published literature provides no firm guidance. Many patients are now on long-term anticoagulation (heparin and its derivatives, or warfarin) or long-term antiplatelet therapy (eg, aspirin, clopidogrel) or are taking other medications that effect platelet function (eg, nonsteroidal anti-inflammatory agents). The risk of discontinuing therapy (eg, thrombosis) must be weighed against the risk of an increased likelihood of a biopsy-induced bleed.
If the clinical service is comfortable discontinuing therapy, remember that one must wait~6 hours after discontinuing heparin and 8 hours (overnight) after discontinuing low-molecular-weight heparin (LMWH), although one recent trial states that one should consider giving the last dose of LMWH the morning of the day before surgery, rather than our standard practice of giving the last dose the night before surgery; again, though, this change should be weighed against the risk of thromboembolism. 21 Current recommendations suggest waiting 5 to 7 days after discontinuing aspirin and 7 to 10 days after stopping clopidogrel (Plavix) and ticlopidine (Ticlid). 22 Nonsteroidal anti-inflammatory drugs (NSAIDs) are a large family, but they do not irreversibly affect platelet function the way that aspirin does; thus, our hematologists state that a 24-hour discontinuation before the procedure is generally sufficient. Warfarin's duration of action varies widely, depending on many factors (dose, liver function); in general, we discontinue warfarin about a week ahead of time and recheck an INR the morning of the procedure. In one trial of patients on long-term anticoagulation undergoing colonoscopic polypectomy for polyps of less than 1 cm, warfarin was discontinued 36 hours before the procedure, and the average INR on the day of the procedure was 2.3. No bleeding complications were identified with 41 polypectomies in 21 patients. 23 In all cases, reinstitution of medications after a procedure should be individualized. 22 For patients in whom even short-term discontinuation of warfarin therapy is felt to be too risky, our standard practice is to discontinue warfarin 5 to 7 days before the procedure and replace with LMWH. The LMWH is then discontinued the night before the procedure and restarted the night of the procedure. Warfarin therapy is reinitiated on the next day. As always, close consultation with the referring service leads to optimal patient management.
Should one ever perform an interventional procedure in a patient who has recently taken an aspirin or NSAID? There is no good evidence-based answer to this commonly occurring and vexing issue. In an informal survey of colleagues who perform many ultrasound-guided procedures, some laboratories hold firm to this rule and refuse procedures until the requisite time off the drug has passed, primarily over fear of litigation in the setting of an adverse outcome rather than any true scientific sense that this is intrinsically dangerous. Other colleagues share our opinion that this is too severe a practice, potentially leading to great patient inconvenience (eg, the patient who lives 5 hours away and has taken 2 days off work for a liver or thyroid biopsy, having failed to get the message that he should discontinue his daily baby aspirin 5 days before). After a thorough discussion of the possible theoretical increase in risk with the patient and giving him or her the option of rescheduling for a future date, we will typically go ahead and perform the biopsy in this setting; conversely, in the retired patient who lives 10 minutes from our hospital and for whom it is no true inconvenience to reschedule, we will usually delay the procedure until these drugs have been stopped for an adequate period.
There are data to support performing low-risk biopsies in patients on aspirin or NSAIDs. First, an editorialist states that maintaining patients who are at substantial risk for cardiovascular events on aspirin yields good results for therapeutic endoscopic procedures. 24 Second, many open surgical procedures, especially vascular, are performed in patients who are anticoagulated or on aspirin due to a favorable risk-benefit ratio. Third, a UK expert writing on guidelines for liver biopsy states that BIeven though the ingestion of aspirin and other NSAIDs in the week prior to invasive intervention is a recognised contraindication by several authoritiesIthere are, to our knowledge, however, no convincing data to support this as a contraindication to percutaneous liver biopsy. [ 25 Fourth, a review of the issue of low-dose baby aspirin in patients undergoing ultrasoundguided transrectal biopsies of the prostate identifies 2 studies that found no increased risk of hemorrhage in the groups on aspirin. 26 Finally, a Radiological Society of North America presentation in 2005 looked specifically at the risk of significant hemorrhage resulting from image-guided core biopsy in patients taking aspirin. 27 In this study of 6073 biopsies, the authors concluded that Bthere is an elevated risk of significant bleeding complications in those patients taking aspirin at the time of percutaneous biopsy. However, this risk is small and should not preclude biopsy in most cases.[ In fact, although not statistically significant, in their subset of patients undergoing liver biopsy, the hemorrhage rate in patients taking aspirin was approximately half that of those not taking it (0.46% vs 0.93%). In summary, as in all of medicine, optimal care results from treating each patient as an individual and fully discussing the pros and cons of any potential course of action so that the patient may make an informed choice.
Pain Management
Adequate pain control is not only a moral imperative, but it has high political priority as well. Pain management guidelines implemented by the Joint Commission on Accreditation of Healthcare Organizations in 2001 mandate regular assessment of pain and the establishment of policies and procedures that support the appropriate use of pain medication. 28 A comfortable patient makes an abdominal biopsy a much easier procedure all the way around! Pain management can be simplified into the BGolden Rule[; how would you like yourself or your mom to be treated? There are 3 components to adequate pain relief: psychosocial, local anesthesia, and moderate sedation.
Psychosocial
It has been shown again and again that obvious care, concern, and warmth from the medical team result in decreased patient anxiety and perceived pain. Follow common sense tactics such as making sure that the patient is at a comfortable temperature, that there are no bright lights in the patient's eyes, and so on. Think about how you prepare the patient. For needles that can be test fired before use (read the package insert; some of the older devices recommend against testing), there is a world of difference between facing the patient with the needle fully visible, close to his face, and stating, Byou will hear a bang from the gun as I fire it, 
Local Anesthesia
We use 1% lidocaine buffered with 8.4% sodium bicarbonate in a 9:1 ratio. Although somewhat controversial, the buffering is generally reported to decrease the Bstinging[ sensation of the lidocaine injection. 30 On a practical note, the rate of injection is often the most important factor for making the injection more tolerableVslow is good. When performing local anesthesia, start with a subdermal injection of 2 to 3 mL of lidocaine using a 30-gauge needle (note how small this is, rather than the typically provided 22-or 25-gauge diameters), followed by deeper anesthesia with a 22-gauge spinal needle (through the biopsy guide, if you are using one). This technique ensures a cylinder of anesthesia along the path of the biopsy and gives a Bpreview[ of the biopsy trajectory; the latter is useful if there are ribs or other structures to be avoided along the way. Make sure that all air has been purged from the syringe and needle as air can cause obscuration of the needle or target ( Fig. 1 )! Be sure to place several milliliters of lidocaine directly on the peritoneal surface and at the liver (or other organ) capsule. Do not puncture the liver or other visceral organ because anesthetizing the liver parenchyma will not decrease the pain of the procedure and may increase the rate of bleeding. Use lidocaine liberally. We routinely give 10 mL, and there is no risk of lidocaine toxicity in giving 20 mL as necessary. More specifically, the maximum percutaneous dose of lidocaine without epinephrine in healthy adults is 4 mg/kg, up to 300 mg. Because there is 10 mg lidocaine/mL in a 1% solution, this represents a maximum dose of 20 to 30 mL for most patients. Busy physicians take note: lidocaine requires time to diffuse through the tissues, so allow a few minutes before biopsy after local anesthetic administration to minimize discomfort.
Moderate Sedation
The third tool for pain management is moderate sedation (previously referred to as Bconscious sedation[). If the patient is treated appropriately, and copious local anesthetic is properly administered, moderate sedation is usually not necessary for routine liver biopsies; however, if a nurse is readily available, if the biopsy looks to be particularly difficult, or if the patient is particularly anxious, we will certainly use intravenous medications, typically fentanyl (Sublimaze) and midazolam (Versed). We almost never use moderate sedation for thyroid biopsies, superficial lymph node biopsies, thoracenteses, or paracenteses. Conversely, transvaginal biopsies may be quite painful, so moderate sedation is almost always used here.
If moderate sedation is used, make sure that it is done safely. Most hospitals now require special credentialing and privileging to perform sedation, and many also require consent for the sedation as well as the procedure itself. The medications should be administered in small aliquots, typically 50 Kg of fentanyl and 1 mg of midazolam, although in elderly, very sick, or small patients, we will often halve these doses. Always monitor oxygen saturation, pulse, and blood pressure throughout the procedure and afterward in the dedicated recovery area. Oxygen, suction, and airway management equipment should be readily available. Although almost never needed if fentanyl and/or midazolam are appropriately administered, reversal agents (naloxone and flumazenil) should be easily accessible. Keep your advanced cardiac life support skills current.
Infection Precautions
To drape or not to drape? We always drape the probe for guided biopsies (for thoracenteses and paracenteses, we usually mark the spot and do not use the transducer during needle placement). I am not aware of any literature that documents that this extra step decreases the risk of infection. In fact, several very experienced centers of excellence (Mayo Clinic, Italian groups) do not sterilely drape the probe unless the patient is known to have HIV infection and instead simply cleanse and disinfect the transducer before and after each biopsy; they have had no known issues with this protocol. The disadvantages to draping include time, cost, and potential degradation of image quality (although the latter is more theoretical than real in our opinion). If chemical disinfection is used (eg, alcohol, povidone-iodine [Betadine]), ensure that the substance used is compatible with the transducer surface and manufacturer's recommendations.
Skin Preparation
We now use chlorhexidine 2%/isopropyl alcohol 70% (Chloraprep) rather than povidone-iodine 10% (Betadine). Both are adequate, but the former has better antimicrobial activity, does not stain or itch, and works quicker. Read the package insert for application instructions, and take care to apply with a back-and-forth action for a full 30 seconds, and then let air dryVdo not blot or wipe. Only 1 application is required.
Needle Safety
Be careful! There is a veritable alphabet of pathogens to be wary of. In addition to HIV, there are a variety of hepatitis FIGURE 1. Inadvertently injected air obscuring the target. A, White arrow on CT denotes a soft tissue mass that was later biopsy proven to represent peritoneal carcinomatosis from rectal cancer. The high-density structure just anterior to the nodule is a hepatic arterial infusion pump. B, Arrow denotes nodule on ultrasound. C, Although the lidocaine syringe was flushed of air, the dead space in the numbing needle after the stylet was removed contained enough gas to seriously degrade the ultrasound image. Note how the nodule is now barely visualized behind the shadow caused by the injected air.
strains which currently run from hepatitis A through G. The most important of these are hepatitis B virus, for which a vaccine is available (make sure to check your antibody response to ensure you are adequately immunized), and hepatitis C virus, for which no vaccine is available. Despite all of our precautions, we average about 1 needlestick in our laboratory every year. Protect yourself, the sonographer you work with, and the cytopathologist you are passing the needle to.
OTHER BIOPSY ISSUES Guidance
Mechanical biopsy guide versus freehand. Both systems work well if the operator is comfortable with the technique. Freehand technique offers the possibility of better needle visualization (more specular reflection if angles are chosen appropriately) but generally requires more skill and experience. In one study, a phantom model of lesions in the human liver with simulated overlying ribs was used to compare freehand and probe-guided techniques 31 ; the authors concluded that there was a time benefit to the use of probe guides but that this benefit was greatest for inexperienced operators. In our laboratory, most deep abdominal biopsies are performed using a biopsy guide, whereas superficial biopsies (eg, thyroid, breast, groin) are performed freehand. Remember, though, that a guide is just a guide, not a guarantee, particularly with thin needles, cirrhotic (hard) livers, and/or any firm overlying structures (eg, ribs) that may deflect the needle (Fig. 2) . If consistent deviation to one side is observed, one can adjust the projected trajectory outside the lesion to compensate for the amount of deviation (similar to compensating for wind or elevation issues through the site of a rifle) (Fig. 3) .
Role of the Sonographer
Some laboratories have the radiologist guide the procedure while the needle is placed; this requires more manual dexterity but allows more direct control of needle placement. However, in our laboratory, the sonographers scan and guide biopsy procedures for several reasons: they are usually the best technical scanners; the large number (~2400/yr) of needle guidance procedures done by ultrasound in our laboratory FIGURE 3. Compensating for needle deviation. This challenging peripancreatic mass biopsy was unsuccessful for the first 2 passes because the needle kept deviating medially from its predicted path, likely due to overlying fibrous tissue. A, CT shows mass (black arrow) directly in front of inferior vena cava (''IVC''), posterolateral to portal vein confluence (''PV''), and behind artery (''A'') and common bile duct (''CBD''). For the third attempt (ultrasound shown in B), the trajectory (dotted biopsy guide line) was placed outside the lesion by the amount of predicted deviation, and the needle tip (arrow) was successfully introduced into the lesion. Pathology returned unusual inflammatory pseudotumor.
FIGURE 2.
Needle not following trajectory predicted by the guide. This lesion (metastasis from pancreatic cancer, arrowhead in CT [A]) had to be fine-needle aspirated 3 times to return the diagnosis (metastatic pancreatic adenocarcinoma). Because the 20-gauge needle was deflected by overlying tissues, the first pass was lateral (B) to the lesion (arrowhead). The next pass (not shown) was medial to the lesion, whereas the third pass (also not shown) was in the tumor. Arrow points to the needle tip.
contributes to a high level of expertise and experience by the sonographers in the face of a constantly changing group of residents and fellows, thereby enabling us to deliver more uniform quality; the division of labor enables all participants to concentrate on a single task (sonographers on the probe and guidance, and sonologists on passing the needle and managing the specimen); and the fact that the most difficult and challenging biopsies require abdominal compression, awkward transducer angulation, and/or prolonged targeting, which can be nearly impossible to perform by a single operator.
Image Optimization
This is perhaps one of the most important aspects of any nontrivial biopsy. First, choose the correct transducer. To quote Prof Faye Laing, Bin ultrasound, always start high, then go low.[ That is, attempt to use the highest possible frequency transducer. Many superficial liver lesions, especially those in the left hepatic lobe, can be imaged with high-frequency linear transducers (the Bsmall parts[ probes); the better depiction of the target inherent with these transducers makes biopsies easier and enables one to reliably hit smaller masses (Fig. 4) . If the lesion cannot be seen with a high-frequency linear transducer, try a lower-frequency linear (Bvascular[ probe) or high-frequency curved linear array. If those do not work, move to a low-frequency curved linear probe, and only if all of these fail, use the small footprint sector/vector/phaser probe. These latter probes are often necessary for deep lesions that are accessed between ribs, but should not generally be your first choice. Second, optimize your gray-scale image. Zoom in, put your focal zones at the area of interest, and try harmonics; we have found that compound imaging technology greatly improves needle visualization.
Seeing the Needle
After the gray-scale image has been optimized, what can one do to help visualize the needle? Obviously, the more perpendicular the sound beam is to the needle, the stronger the reflection will be. Move the inner stylet in and out without actually moving the outer needle; this saves tissue trauma and often is all that is needed to find the needle. Rotating the needle often allows optimization of the specular ultrasound reflection from asymmetric needle tips. If these maneuvers fail, then judiciously moving the needle back and forth is often useful. Echogenic needle coatings are not a cure-all, but do aid in needle detection 32 with very little additional cost. Some authors have described using color Doppler to locate a moving needle tip, but in our experience, the artifact associated with this generally limits its usefulness.
Patient Positioning
Many practitioners inadvertently assume that biopsy should be performed with the patient in supine position, (Fig. 5) . Spend time scanning and preparing ahead of time with this in mind, and potentially difficult procedures can often be easily converted to very manageable ones.
Core Versus FNA
The choice between cytology (FNA) and pathology (core) is multifactorial and is often based on institutional access and expertise. If cytology service is not available during the procedure to assess the adequacy of a specimen, a core biopsy is often the best choice. The smaller needles possible with cytology (20-to 25-gauge) are associated with a procedure that is likely safer as well as more comfortable for the patient. In general, cytological aspiration should be considered in patients with a known malignancy and a high pretest probability that the area on which a biopsy will be performed is a metastasis; hypervascular lesions; masses surrounded by certain structures (ie, bowel, blood vessels) where trauma needs to be minimized; and epithelial tumors (adenocarcinomas and squamous cell carcinomas). Although there is a great variety of opinion on this matter, 33 our cytology team believes that better FNA samples are obtained with the smallest possible needle (eg, 25-gauge for a thyroid FNA) and no suction, just vigorous back-and-forth motion to pack the needle with cells. Larger needles and syringe suction give fewer diagnostically adequate samples due to dilution with blood products 14 and are reserved for the rare scirrhous lesion that fails to shed cells with the smallest gauge needle. Interestingly, and perhaps somewhat counterintuitively, there are very little data suggesting that appropriate use of an 18-gauge needle is any more dangerous than using a smaller FNA needle. 34 Biopsies are usually more appropriately performed using automated cutting needles in cases other than those just listed, particularly lymphoma, RCC, and hepatoma. Although both work well, we generally prefer the newer cylindrical full-bore cutting needles to the older side-notch needles, because one obtains significantly more tissue per core for analysis than the former for a given puncture diameter (Fig. 6) . If a small bowel loop needs to be traversed to get to the mass, try to use no larger than a 20-gauge needle. Core biopsy specimens can be assessed for adequacy by either Btouch-prep[ (the cytology team rolls the core on a glass slide and performs cytological analysis on the shed cells) or, often with high accuracy, by simple visual inspection (Fig. 7) . Interpretation of cytology specimens is not only operator dependent but also inappropriate for some tumor types, and thus, the decision to obtain cytological or pathological specimen in a given patient should be individualized on a case-by-case basis; consult with your clinicians and pathology experts regarding the clinical question that needs to be answered and the best method for getting to that answer.
Coaxial Versus Multiple Separate Passes
Should one place a larger bore introducer needle and sample (either FNA or core biopsy) multiple times through this, or should one serially perform multiple separate passes with a smaller bore needle? As with many of the Bcontroversies[ regarding technique in the biopsy arena, there is a paucity of hard, evidence-based data regarding this question. Our general preference and practice is to perform multiple separate passes with a smaller bore needle. An exception is made when the initial needle placement is very challenging; in these cases, we will place an introducer and sample coaxially through it. One article suggested that the strategy of multiple separate needle passes might have a higher successful yield rate because slightly different areas of the target (due to the inevitable slight differences in needle positioning inherent with this technique) are sampled, thereby avoiding repeatedly sampling a necrotic or nondiagnostic area. 35 Another theoretical advantage to this technique is that if samples are performed during suspended respiration (as we always do), one does not shear or tear the capsule (liver, kidney, pleura, peritoneum) but rather makes focal discrete punctures that may have less tendency to bleed. Disadvantages to this strategy include multiple holes in the covering capsule (as opposed to just 1 hole with coaxial technique) and the fact that, for very difficult and challenging biopsies, one has to successfully navigate the needle to the lesion multiple times.
The coaxial technique makes it easy to obtain multiple samples once the introducer needle is placed. There is generally only 1 hole in the capsule. Normal tissue is relatively protected from the trauma of multiple needle passages. Disadvantages of the coaxial technique include potential shearing of the capsule (because the introducer is generally left in during quiet respiration between samples), a larger puncture hole in the capsule, and repetitive sampling of the same area. A postulated but unproven advantage is less chance for track seeding because the needle that samples the tumor is withdrawn through the inside of the introducer needle. The issue of the true risk of track seeding is very controversial, but 1 article that evaluated the use of a 17-gauge introducer with an 18-gauge biopsy needle in 128 patients with proven HCC found a 0% incidence of track seeding with a mean follow-up of 410 days 36 ; however, 8 (6.25%) of these patients also had an episode of bleeding within 24 hours of biopsy that required hospital admission, fluid resuscitation, and/or transfusion. This 6.25% bleed rate is significantly higher than the 0% to 1.4% rates published in several other series, and it is possible that this increased risk is related to the coaxial technique.
Needle Technique
In choosing a needle path, consider the intervening structures (ie, attempt to avoid vasculature and bowel, although small bowel can generally be traversed safely with a 20-to 22-gauge needle), and usually select the shortest path from skin to lesion. The needle should be advanced during suspended respiration with a firm, continuous motion to minimize pain and to keep the needle on target. Also, the needle tip is usually much easier to see when it is in motion. Slow and tenuous needle passes tend to deflect rather than puncture structures (like the liver capsule), decrease the ability to see the needle tip, and increase patient pain, especially when traversing the peritoneum or visceral structures sensitive to stretching; thus, a brisk puncture is optimal when passing through these coverings.
Is biopsy through ascites safe? In a word, yes. Older, anecdotal teachings stated that biopsy through surrounding However, several studies have shown that, at least in the case of the liver, the presence of ascites does not alter complication rates 37, 38 (Fig. 8 ).
Postprocedure Imaging
There is no consensus as to whether one should image after a biopsy to assess for potential complications. The Bno[ group feels that the patient should simply be assessed clinically (Btreat the patient, not the lab test[ school of thought), that most bleeds are small and resolve spontaneously, and that imaging of these asymptomatic hemorrhages leads to unnecessary excitement and overtreatment (Fig. 9) . Others state that postprocedure imaging is useful in predicting high-risk groups for more careful follow-up. For example, a recent article by Kim et al 39 showed that a negative Doppler biopsy track immediately after biopsy had a 100% negative predictive value for postprocedural hemorrhage, whereas Doppler detectable flow in the track and again at 5 minutes later had a positive predictive value of 75% for postbiopsy bleeding (Fig. 10) .
Monitoring
Following an intra-abdominal biopsy, we observe the patient for~4 hours in a dedicated recovery area with frequent vital sign monitoring; this is a Joint Commission on Accreditation of Healthcare Organizations requirement if moderate sedation has been administered. We do not obtain routine postprocedure hematocrit/hemoglobin levels if the patient is asymptomatic. The patient must be awake, alert, and able to hold down fluids before discharge. The patient should have a ride home from the hospital, appropriate instructions about what to do if questions or complications arise, and know the protocol for contacting his or her physician to discuss the biopsy results. Good communication and patient teaching help prevent unfortunate outcomes such as the patient who had a liver biopsy, returned to his home 2 hours away, had mild pain, and went to the local emergency room where the on-call surgeon heard the words Bliver biopsy today[ and then performed unnecessary exploratory celiotomy for a small bleed that easily could have been managed conservatively.
SPECIFIC SITES Liver
The liver is likely the most commonly percutaneously biopsied solid abdominal organ. Liver biopsies can be divided into Bmedical[ biopsies, acquiring tissue from a random site in the hepatic parenchyma to assess for diffuse disease (eg, staging hepatitis C damage, assessing cirrhosis, or grading rejection after transplant), versus Bsurgical[ biopsies, targeting a specific suspicious lesion in the liver. The former has often been (and still often is) performed Bblindly[ with just FIGURE 11 . Biopsy complication. Severe pain after a nonradiology-performed ''blind'' liver biopsy (no image guidance was used) prompted a postprocedure CT. Scout view (A) denotes a large mass in the right abdomen (black arrows), shown to be a large hematoma (white arrows) on axial imaging (B). The patient required several blood transfusions but recovered. palpatory guidance, but intuition and data suggest that sonographic guidance leads to a safer procedure (Fig. 11) . Left lobe access for ultrasound-guided medical liver biopsy is perhaps minimally easier and safer and is therefore our first choice, but we will readily move to the right lobe if access is better. A subcostal approach during suspended inspiration is definitely preferred, but we often use an intercostal approach as necessary. Needle insertion below the 12th rib posteriorly or the 10th rib laterally should avoid pleural transgression 40 ; however, we have not experienced a pneumothorax from a transpleural needle passage as long as we punctured below the aerated lung (which can easily be seen on ultrasound). We typically find that a single, 18-gauge, 3.3-cm-long core using a full-bore-type needle (vide supra) provides sufficient tissue, but work closely with your clinicians and pathology departments to determine the specimen volume required.
Surgical (targeted lesion) biopsies by definition limit the options available for approach to the lesion. Close attention to detail and careful application of the principles already covered will maximize success; many of the principles discussed above were written based specifically on experience with liver biopsies. However, several other relatively unique issues apply to the liver and not as much to other deep abdominal or pelvic biopsies.
Intercostal biopsies, often necessary for high dome lesions, run the risk of traversing the pleural space (as expected, the risk is higher at 10 to 11 than it is at 11 to 12). Pneumothorax, however, is extremely unusual if sonographic guidance is used to identify and consciously avoid aerated lung parenchyma (Fig. 12) .
Biopsy through the portal vein should be avoided if possible, but traversing a large branch of this vessel to reach the target (Fig. 13 ) may be necessary; this is safe (think of the trauma to the liver associated with a transjugular intrahepatic portosystemic shunt procedure). If required, thrombus within the portal vein itself can be biopsied to determine whether clot is bland or malignant, 41 information that is often crucial to patient management decisions. Similarly, hepatic vein branches can generally be safely traversed with a biopsy needle, although again, this should be avoided when possible. Conversely, visible, and especially central, branches of the hepatic artery should always be actively avoided. Should hemangiomas be biopsied? We have performed core biopsies and FNAs on many hemangiomas without incident in our careers. Although there is no reason to sample a classic-appearing hemangioma in a low-risk patient 42 ; many patients have atypical-appearing hemangiomas or high-risk histories, leading to a very reasonable desire from the clinical service for definitive tissue assessment. Given that hemangioma incidence in the adult population has been reported in up to 20%, 43 it is inevitable that biopsy will be performed on these lesions, and there is no convincing evidence to suggest that it is unsafe to do so.
If multiple samples from the center of a lesion are nondiagnostic, this may be due to central tumor necrosis; to obviate this problem, sample the rim of the lesion where more viable cells may be present (Fig. 14) .
Whenever possible, attempt to perform biopsy on a lesion through a cuff or rim of normal overlying liver. Although there are no good data to support this recommendation, and although we will perform biopsy directly into a lesion if no access is possible through normal liver, it makes sense that an overlying layer of normal hepatic parenchyma (Fig. 15 ) may decrease postbiopsy bleeding and possibly tumor seeding as well.
Should potential hepatomas be biopsied? If necessary, yes, although this is controversial. Hepatomas may have a higher risk of bleeding (Fig. 16 ) and/or seeding (Fig. 17) than other pathologies. Therefore, intersociety guidelines have been proposed 44 that state that clinical and noninvasive imaging data may be used in certain circumstances to reliably make this diagnosis without biopsy. For example, a lesion of greater than 2 cm that has arterial-phase hypervascularity on CT or MRI, combined with a serum AFP of more than 400 ng/mL, does not need tissue diagnosis. In equivocal cases, though, it is reasonable to biopsy a potential HCC for tissue characterization.
Spleen
To quote from a 1999 Duke article, 45 Bthe reluctance to perform splenic needle aspiration comes from the unfounded (italics added) perception that this procedure is a dangerous one with a high risk for hemorrhageI.[ The belief that splenic sampling is unsafe is not backed by data; for example, Soderstrom 46 reported more than 1000 splenic FNAs that were performed without complications. Although, as with all invasive procedures, complications may occur, 47 splenic biopsy complication rates are well within the limits associated with biopsy of other abdominal organs. 45 A biopsy can be safely performed on the spleen under sonographic guidance, 48, 49 even in children. 50 A 2007 study of 43 splenic biopsies showed that 18-gauge needles had a higher diagnostic rate compared with 21-gauge needles, with no increased incidence of complications, and thus recommended the use of 18-gauge cutting needles for ultrasound-guided splenic lesion biopsy. 51 Although this conclusion has been reached by other authors as well, close communication with the clinical team and pathology department provides optimal patient care; we may start with core biopsy for suspected lymphoma (Figs. 18 and  19 ) but will otherwise often start with FNA and then move to core only if necessary.
Pancreas
A biopsy can be safely performed on the pancreas under sonographic guidance. 52, 53 Biopsy for suspected adenocarcinoma is usually only performed when the lesion is thought to be unresectable; if there is any chance for surgical extirpation, the patient typically goes straight to the operating room, thereby bypassing the potential minimal risks and problems inherent in any type of image-guided biopsy. Percutaneous biopsy often necessitates a transgastric approach (Fig. 20) ; either FNA or core technique can be used. We generally start with FNA, but given the scirrhous nature of most adenocarcinomas, insufficient tissue is not infrequently obtained; therefore, in those cases, we escalate to core biopsy.
Although I am not aware of good evidence to support the recommendation that normal tissue should always be avoided to minimize the risk of biopsy-provoked pancreatitis, 54 this seems like a reasonable tenet and can usually be easily implemented. Seeding after biopsy is generally not a clinical problem given the dismal prognosis of patients with this disease, but animal studies suggest that 100 to 10,000 cells may be deposited along the track with just one pass 55 ; potential improvements in chemotherapy in the future may make this consideration more important as patients survive longer. A recent trend includes a movement toward endoscopic ultrasound (EUS)Yguided FNA of pancreatic adenocarcinoma, away from image-guided percutaneous sampling, FIGURE 17 . Striking perihepatic rind of tumor seeding (arrowheads) following invasive needle procedure (percutaneous ethanol injection of HCC at an outside hospital 1 year previously). AFP was more than 1,000,000 ng/mL! FIGURE 18. Splenic lymphoma in a patient with Wegner granulomatosis. A, The most inferior slice of a chest CT demonstrates a hypoattenuating mass in the anterior margin of the spleen (white arrow). B, Diagnostic ultrasound confirms that this lesion can be seen at sonography (graticules). C, Ultrasound-guided core biopsy makes the diagnosis (arrow points to the needle tip). Note how a small footprint transducer was necessary for this intercostal biopsy. 56 less risk of pancreatitis, and an overall safer procedure. 55, 57 However, EUS is a specialty procedure with limited penetration in private practice and does not allow for reasonable size core biopsies.
Other pancreatic masses besides adenocarcinoma (eg, various solid or cystic primaries and potential metastases to the pancreas) can easily be sampled. In addition, pancreatic gland biopsy of transplants (Fig. 21) is often performed to assess for rejection in those who have received a pancreas transplant for diabetes. Postbiopsy pancreatitis in this setting is a rare event; at our institution, there was only 1 significant complication of pancreatitis in 180 pancreas transplant biopsies (oral communication with transplant surgeon Jon Ordorico, August 07, 2007).
Kidney
Tissue sampling of the kidney has classically been discouraged due to concerns over poor histological accuracy and the fear of tumor seeding. However, a series of recent articles 58Y63 discusses the growing utility of this technique as histology techniques have improved; in addition, the risk of seeding, although real, is very small. 62, 64 Given the rapid growth of percutaneous ablation techniques for small RCCs, 65, 66 preprocedural lesion biopsies are becoming very common. Other indications for mass biopsy include possible lymphoma (Fig. 22) and distinguishing an RCC from a renal metastasis in the face of widespread tumor of another type (Fig. 23) . Another common indication for ultrasound-guided renal biopsy is assessing for rejection in renal transplants; 17,249 renal transplants were performed in the year 2005 in the United States alone.
67 Figure 24 provides an unusual example of a focal mass biopsy in a renal transplant. Although many people prefer core biopsy, there is some literature that FNA seems to perform as well (or better) for most of the common lesions, 62 but as with all cytology techniques, accuracy depends heavily on local expertise in this specialized area. There is debate about whether coaxial technique is useful in preventing tumor seeding; we feel that there are no convincing data that the use of an introducer needle helps decrease seeding and therefore only use coaxial technique when we feel its use is warranted for other reasons.
Adrenal
Although the number of benign adrenal adenomas on which biopsy was performed has decreased with the introduction of dedicated adrenal CT and MRI for adrenal mass characterization, 68 percutaneous imaging-guided biopsy is still requested for tissue confirmation when these studies are inconclusive, and it is important for clinical management. Metastases to the adrenal gland (most from primary lung cancer) are the most commonly identified adrenal mass at biopsy. Although some consider biopsy of potential adrenal cortical carcinomas (ACCs) relatively contraindicated due to FIGURE 20 . Two different patients who underwent successful ultrasound-guided needle sampling of pancreatic adenocarcinoma. Note transgastric (arrowheads) passage in both cases (arrow points to the needle tip). A, FNA sufficed for this lesion. B, A 20-gauge core biopsy was necessary for tissue diagnosis in this patient. the risk of seeding and difficulties in pathological differentiation between ACC and degenerated adenomas, 69 we will occasionally perform this procedure in the correct clinical situation. Functioning tumors of the adrenal gland, such as pheochromocytomas, do not require biopsy; one should strive to avoid performing pheochromocytoma biopsy due to the risk of hemodynamic instability.
Some radiologists prefer CT guidance for adrenal biopsies, particularly on the right side where a CT-guided paraspinal approach obviates a transhepatic path, thus avoiding the superficial and deep liver capsule. However, if we are able to visualize the mass sonographically, biopsy is often performed under ultrasound guidance for the many other reasons listed above. Right-sided lesions are typically approached transhepatically (Fig. 25) , whereas left-sided lesions may be targeted through a left lower intercostal space with the patient in a right lateral decubitus position. Ultrasound-guided FNA of the adrenals has been shown to be as safe and accurate as CT-guided FNA in patients with lung cancer. 
Bowel
Two issues pertain to biopsy and the bowel: is it safe to pass through the gastrointestinal (GI) tract en route to a target, and when can biopsy be used for lesions intrinsic to the bowel?
The answer to the first question is yes. 71 We routinely pass needles through the stomach (Fig. 20 ) and small bowel (Fig. 26) to reach the target lesion in certain situations. In Brandt's 1993 study on percutaneous biopsy of the pancreas, there were 66 documented needle passes through the GI tract (41 gastric, 18 small bowel, and 7 colonic, all of the latter with a 21-gauge needle) without any related complications. 72 The stomach has a muscular thick wall that renders it relatively forgiving to puncture; a rabbit study suggested that 18-gauge transgastric Tru-Cut cores can be used without fear of bleeding, leakage, or peritonitis. 73 Fine-needle aspiration traversal of the small bowel is generally considered safe in immunocompetent patients. 74 Passage through the colon is the most problematic area. Although several articles report no problem with this approach, 72, 75 with one group stating Bthe risk of peritonitis associated with colonic transgression with an 18-or 20-gauge core needle biopsy appears to be smallI, [ 71 we generally try to avoid this approach, especially with large-gauge needles. 76 If a transcolonic approach is considered, a cleansing bowel prep may be prudent.
In a study on ultrasound-guided biopsy of small lymph nodes in the abdomen and pelvis, the authors state, BWe made no particular attempt to avoid transgression of intervening small bowel or colon; in fact, with compression, it is usually impossible to differentiate bowel from mesenteric or omental fatty tissue. [ 14 None of their patients received antibiotics or had complications related to bowel perforation, but they did suggest that prophylactic antibiotics may be indicated in those patients in whom passage through the colon is anticipated. As expected, complications with transenteric passage have been reported, including peritonitis 34 and infection of an adjacent fluid collection. 77 Although there is much contradictory and/or incomplete data on this topic, our approach can be roughly summarized as follows: avoid bowel if easily possible; if bowel must be transgressed, use the smallest feasible needle diameter; FNA and large core (18-gauge) sampling through the stomach are very safe; FNA and, if necessary, 20-gauge core sampling through small bowel are reasonable; avoid colon if at all possible, and if necessary to pass through colon, try to stay with FNA.
Many reports demonstrate the utility of FNA for intrinsic lesions of the alimentary canal. 78 Fine-needle aspiration is particularly useful in patients whose lesions cannot be reached by endoscopy, or who are poor candidates for endoscopy. 79 Percutaneous core biopsy of bowel wall masses is also safe 71,80Y82 and allows a definitive diagnosis to be made (Figs. 27 and 28) 83 in difficult cases when other 
Peritoneal and Retroperitoneal
Ultrasound should be the method of choice for tissue sampling of most of these masses. In the past, many radiologists assumed that nonsolid organ masses could only be seen and biopsied under CT; we now know that, particularly if armed with a good-quality diagnostic CT or MRI ahead of time, most mesenteric and retroperitoneal masses can be found and sampled at sonography. 85 In a study on performing biopsy on small lymph nodes of the abdomen, pelvis, and retroperitoneum, Fisher et al 14 found that sonography was successful 86% of the time; moreover, the average skin-to-lesion distance was reduced with transducer compression from an average of 8.8 cm at CT to 4.5 cm during sonography, a factor that is more important as obesity becomes endemic in our society. In another study on the utility of ultrasound guidance for percutaneous biopsy of mesenteric masses (Fig. 29) , sonography was 95% sensitive and 100% specific at allowing malignancy to be distinguished from nonneoplastic tissue. 71 Firm pressure with the ultrasound probe is a crucial element of a successful procedure, shortening the distance to the target, helping displace bowel out of the needle path, and fixing the target in place (Fig. 30) . Real-time needle tip visualization often converts what would be difficult CT-guided procedures to easy sonographic ones (Figs. 31 and 32) . Ultrasound guidance allows performing biopsy on nodes that, in the past, would have been considered Bundoable[ by CT (Fig. 33) , thereby saving patients the morbidity of unnecessary surgical procedures.
Pelvis
Image-guided biopsy of masses in the pelvis is effective and safe; however, CT guidance has been considered the FIGURE 30 . Retroperitoneal nodes brought closer to anterior abdominal wall with compression. A, CT in a 22-year-old with abdominal pain demonstrates retroperitoneal adenopathy (arrow), as well as bowel wall thickening. Clinical service asked us to target nodes, although the thickened bowel wall would also have been an acceptable target. Ultrasound images before (B, note how lesion is at about 6-cm depth with gentle transducer contact) and after (C, note how lesion has moved to only 3-cm depth with firm pressure) compression show how these retroperitoneal structures can be brought much closer to the transducer with pressure, as well as displacing and/or compressing any potential overlying bowel loops. Arrow in C denotes core biopsy needle tip in node; pathology returned non-Hodgkin lymphoma.
FIGURE 31. Retroperitoneal node successfully sampled after CT failure. A, CT shows bilobed retroperitoneal adenopathy (''R'') between the aorta (''A'') and IVC (''C'') in this patient with a history of prostate cancer. Iodinated contrast could not be administered due to his renal failure. B, Outside hospital attempt at CT-guided node biopsy yielded nondiagnostic samples. Note how IVC cannot be accurately identified during biopsy, although margins of aorta are partially denoted by calcifications. C, These same nodes were successfully sampled using ultrasound and an anterior approach; note how target nodes were brought very close to the anterior abdominal wall with compression (center of node at~3-cm depth). Due to the scirrhous nature of the tissue, it took seven 18-gauge cores to obtain adequate tissue. However, this was easily and safely performed because IVC (''C'') was visualized at real time during all samples. Final pathology confirmed metastatic prostate cancer. method of choice in the past. Recent work has shown that technological improvements in sonography, as well as greater confidence and experience with ultrasound guidance, allow all of the previously described advantages (speed, lack of radiation, cost, real-time visualization, etc) of sonographic imaging to be brought to bear on pelvic lesions. A 2007 study by Yarram et al 86 concluded that the accuracy and sensitivity of ultrasound-guided core biopsies of pelvic masses were higher than those for CT-guided biopsies.
Percutaneous biopsy may be easily performed on large pelvic masses using the techniques already described (Fig. 34) . Ultrasound guidance (using the biopsy guide on the endovaginal or endorectal probe) is particularly suited, however, for deep pelvic masses that are not safely amenable to percutaneous approaches, because transvaginal (Fig. 35) or endorectal access often allows easy tissue sampling. Although most of the biopsies already discussed may be performed with just local anesthesia, passage of a needle through the muscular FIGURE 34 . Large omental metastasis. The patient had ''low-grade'' cervical cancer on Pap smear. Subsequent MRI (A) revealed a large mass (arrow) anterior to the uterus (''U''), with differential including leiomyoma. Simple percutaneous 18-gauge core pelvic biopsy (B) was performed (arrow points to the needle tip). Unfortunately, the final diagnosis was stage IVB squamous cell carcinoma of the cervix. FIGURE 33. ''Impossible'' retroperitoneal node successfully biopsied. A, CT in this patient with pancreatic carcinoma (''C'') and Courvoisier gallbladder (''GB'') shows target node (arrow denoting both node and path needle will take) between aorta (''A'') and cava (''IVC''), and behind superior mesenteric artery and superior mesenteric vein. B, Doppler ultrasound (oriented similarly to CT in A) shows path (dotted biopsy guide line) FNA needle took to reach node (red arrow); unfortunately, cytology revealed node positive disease. vaginal wall is often painful; therefore, we routinely use moderate sedation for all transvaginal biopsies. Endorectal biopsies generally hurt less than transvaginal ones, but there is a probable increased risk of an infectious complication with this approach; we cover all patients undergoing transrectal biopsies with antibiotics.
Biopsy should not be routinely performed on suspected primary ovarian masses because these are generally treated surgically. However, we will readily perform biopsy on presumed metastases (Fig. 36) or even suspected primary ovarian cancers (Fig. 37) when our gynecology-oncology specialists present a good case that sampling of these lesions is in the patient's best interest.
Transrectal biopsies of the prostate will not be discussed in this article, given the copious worldwide familiarity with this procedure, but realize that this experience, with huge numbers of patients biopsied, has shown that the transrectal approach is generally safe and well tolerated. 87 FIGURE 37. Cytological sampling and drainage of ovarian cancer. This 60-year-old with stage IIIC clear cell recurrent ovarian cancer had undergone suboptimal debulking at an outside institution. The patient subsequently presented with nonspecific abdominal and pelvic pain. A, TVUS showed a large cystic mass with mural nodularity (arrow), findings highly suggestive of residual/recurrent tumor. The gynecology-oncology department did not wish to take her to the operating room because of multiple comorbidities, so they requested TVUS aspiration for 2 reasons: first, to confirm cytologically that this was indeed ovarian cancer (it was), and second, to see if drainage relieved her symptoms. If aspiration had provided relief, the gynecology-oncology department would have taken her back to the operating room for additional debulking, despite the surgical risk, but because her symptoms remained the same after removal of 800 mL of fluid (B) (note 18-gauge needle within smaller fluid collection during aspiration), surgery was not performed. 
Chest
Although often underutilized as a guidance modality for thoracic processes (because many radiologists automatically default to CT in the chest), sonography is very useful in tissue sampling of many mediastinal and pleural based masses; please see the recent superb review by Middleton et al 88 for an indepth treatment on the role of ultrasound in this area.
COMPLICATIONS
Percutaneous biopsy is a very safe procedure if performed correctly. Serious complications should be infrequent (G5% bleed rate in most published series) for biopsies that use 18-gauge needles and smaller. Intra-abdominal bleeding is usually the most severe complication, but very rarely needs intervention besides monitoring and supportive care. Infrequently, a transfusion is needed (Fig. 11) , and surgery should be required only rarely. It is important to emphasize that most bleeds after biopsy are minor and require nothing but watchful waiting (Fig. 38) . The patient should be informed before the procedure that damage to structures in the path of the needle (bowel, vessels, other organs) is also possible but unusual. Infection is very infrequent (G1%). Also, mention the possibility of nondiagnosis, potentially necessitating a repeat biopsy or other diagnostic procedure.
FUTURE TRENDS Contrast Agents
Although commonly used outside the United States, radiologists in the United States still wait for contrast agent approval. The recent (October 2007) Food and Drug Administration black box warning for ultrasound contrast agents may delay approval of these agents for abdominal purposes in the United States even longer. As expected, it has been suggested that using these agents will make biopsies easier, particularly for difficult-to-see lesions. 89 
Track Management
Placing a chemical substance (eg, gel foam) into the needle track for hemostasis is occasionally used for very large introducers; injectable Bglues[ have also been proposed for use with thinner 17-or 18-gauge coaxial sets. Alternatively, radiofrequency ablation (Bcauterization[) of the introducer track (Fig. 39 ) may provide both hemostasis and also minimize potential track seeding with malignant cells. 90 None of these 
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FIGURE 38. Small, clinically unimportant hematoma after biopsy. Following transportal biopsy of a liver lesion (Fig. 13) , postprocedure imaging demonstrated this 1.6 Â 7.7-cm hematoma (arrow) in the anterior abdominal wall above the liver puncture site. The patient was asymptomatic, educated about the bleed, and discharged with standard instructions; there were no sequelae.
approaches have gained widespread acceptance, however, because biopsy procedures without these technologies are already so intrinsically safe.
Three-Dimensional Ultrasound
There is a move toward a more clinical use of 3D/4D ultrasound. It has been suggested, for example, that portal vein access during transjugular intrahepatic portosystemic shunt procedures is more effectively performed with 3D ultrasound. 91 Newer electronic matrix 3D technology offers very high temporal (4D) resolution; this allows one to ensure that the biopsy needle is truly within the lesion in 2 different planes, decreasing the chance that partial volume averaging artifact will lead to erroneous needle placement (Fig. 40) . Whether this exciting, rapidly improving technology will prove generally useful in biopsies remains to be seen because 2-dimensional ultrasound guidance is already so safe and effective.
Image Fusion
With the use of spatial localization technology that allows accurate determination of the position and orientation of the ultrasound probe relative to the patient, live ultrasound data can be Bfused[ with corresponding reconstructions from previously obtained CT or MRI scans. This image matching promises huge benefits for ultrasound-guided procedures, whether biopsies or ablations. For example, one could perform a biopsy on a lesion that was only seen on arterial-phase, contrast-enhanced CT but that could not be seen on ultrasound; similarly, one could pass needles under ultrasound Note that the biopsy needle is seen passing into the liver both in longitudinal view (left half of figure, arrow points to the needle) and also in an oblique transverse view (right half of image, arrow points to the needle visualized in cross section). This dual visualization should decrease the chance of partial volume artifact and erroneous sampling outside of a potential targeted lesion (this image was obtained from a medical liver biopsy, hence no focal lesion). Also note that this paired image was acquired at a 27-Hz frame rateVessentially real-time imaging.
guidance with confident knowledge of structures that are to be avoided (like bowel) that may be difficult to see at sonography (Fig. 41 ).
SUMMARY
We have reviewed many aspects regarding the use of sonography to guide biopsies in the abdomen and pelvis. Simply put, ultrasound is generally cheaper, faster, safer, and more effective than CT in most instances in this anatomical region. Keep ultrasound in mind for all biopsies, including those Bimpossible[ retroperitoneal nodes on CT. Our motto is: BIf you can see it by ultrasound, you can hit it![
